source
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…
- Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decisionVertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…